166324-46-5

Upstream product

• 6674-22-2 1,8-diazabicyclo[5.4.0]undec-7-ene 
• 129299-69-0 7-[(acetoxy)-(5-methyl-1-trityl-1H-imidazol-4-yl)methyl]-8,9-dihydro-10-methylpyrido[1,2-a]indol-6(7H)-one 
• 138476-55-8 8,9-dihydro-7-<(hydroxy)<5-methyl-1-(triphenylmethyl)-1H-imidazol-4-yl>methyl>-10-methylpyrido<1,2-a>indol-6(7H)-one 
• 113140-81-1 5-methyl-1-(triphenylmethyl)-1H-imidazole-4-carboxaldehyde 
• 40133-76-4 8,9-dihydro-10-methyl-pyrido[1,2-a]indol-6(7H)-on 

Downstream Products

• 129299-71-4 8,9-dihydro-10-methyl-7-[(5-methyl-1-trityl-1H-imidazol-4-yl)methyl]pyrido[1,2-a]-indol-6(7H)-one 
• 129300-16-9 8,9-dihydro-7,10-dimethyl-7-<<5-methyl-1-(triphenylmethyl)-imidazol-4-yl>methyl>pyrido<1,2-a>indol-6(7H)-one 
• 129299-72-5 (+/-)-8,9-dihydro-10-methyl-7-<(5-methyl-1H-imidazol-4-yl)methyl>pyrido<1,2-a>indol-6(7H)-one 

Relevant academic research and scientific papers

New 5-HT3 (serotonin-3) receptor antagonists, I. Synthesis and structure-activity relationships of pyrido[1,2-a]indoles

A series of pyrido[1,2-a]indol-6(7H)-ones was prepared and evaluated for 5-HT3 receptor antagonist activity. The structural requirements for the 5-HT3 receptor antagonist have been defined as an aromatic moiety, a basic nitrogen, and

Pyridoindole derivatives and processes for preparation thereof

Compounds of the formula: STR1 wherein R 1 is hydrogen, lower alkyl or lower alkenyl, R 2 is hydrogen, lower alkyl, or halogen, R 3 is imidazolyl or pyridyl, each of which may have suitable substituents, and R 4 is hydrogen, lower alkyl, lower alkenyl or

PYRIDOINDOLE DERIVATIVES AND PROCESSES FOR PREPARATION THEREOF

The invention relates to compounds for treatment of nausea and vomiting, of the formula STR1 wherein R 1 is hydrogen, lower alkyl, lower alkenyl or N,N-di(lower)alkylaminomethyl,R. sup.2 is hydrogen, lower alkyl or halogen,R 3 is imidazolyl or